ArticleJAC-antimicrobial resistance2026

Characterization of isolates from two phase 3 uncomplicated urinary tract infection trials (EAGLE-2 and EAGLE-3) that show an apparent ≥4-fold increase in gepotidacin MIC between baseline and post-baseline visits.

Chase A Weikel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.